Back to search results

Understanding Tau in Progressive Supranuclear Palsy

This study aims to understand the amount of Tau protein in the brains of people with Progressive Supranuclear Palsy (PSP). Researchers will use a special scan called a Tau PET scan, which involves a substance called F-18 AV 1451, to measure this protein. You may be able to join if you are over 35, have symptoms of PSP that are gradually getting worse, and have a study partner who can provide information about your daily functioning. The study is looking for 332 participants. The main goal is to see how much Tau protein is present in the brain, with measurements taken over 5 years. The current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 332 participants. The phase of the study is not specified.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, measuring Tau protein, will be assessed at 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02605785

A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy

Recruiting
NAAges 35+InterventionalDiagnostic
Mayo Clinic
~332 participants
Updated 2026-05-05 on ClinicalTrials.gov
What's tested:F-18 AV 1451

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The investigators will be looking at the amount of Tau protein in the brain of patients with PSP.
Measured over 5 years

Conditions

Progressive Supranuclear Palsy

Explore related trials

Progressive Supranuclear Palsy

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Jennifer Whitwell, PhD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Sarah M Boland, CCRP
[email protected]
507-284-3863
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Must be over 35 years of age and present with gradual progression of PSP-related symtoms
Must have an informant or study partner that can provide independent information of functioning.
Must meet criteria for possible or probable Progressive Supranuclear Palsy. To fulfill criteria for possible PSP, subjects must have a gradually progressive disorder with either vertical (upward or downward) supranuclear palsy or both slowing of vertical saccades and prominent postural instability with falls in the first year of disease onset. To fulfill criteria for probable PSP, subjects must have vertical (upward or downward gaze) supranuclear palsy and prominent postural instability with falls in the first year of disease onset.
Subjects with concurrent illnesses that could account for their symptoms, such as traumatic brain injury, encephalitis, strokes or developmental syndromes will be excluded.
Women that are pregnant or post-partum and breast-feeding will be excluded.
Subjects will be excluded from the study if they have any of the following genetic conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome, hypogammaglobulinemia, Wiskott-Aldrich syndrome, and Down's syndrome.
Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma, intracranial neoplasm or large cortical infarcts), or if they are medically unstable or are on medications that might affect brain structure or metabolism (e.g. chemotherapy).
Subjects will also be excluded if they do not have an informant, or do not consent to research.

What this trial measures

  • The investigators will be looking at the amount of Tau protein in the brain of patients with PSP.5 years